TO EVALUATE THE EFFICACY AND SAFETY OF NMN AS AN ANTI-AGEING SUPPLEMENT IN MIDDLE AGED AND OLDER (40-65 YEARS) ADULTS.

Not Applicable

Completed

• Registration Number: CTRI/2021/03/032421
• Lead Sponsor: Abinopharm Inc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-09-09
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Male/females of 40 to 65 years of age

2. Body Mass Index (BMI) between 18.5 and 35 kg/m2

3. Able to provide written Informed Consent

4. Able to follow verbal and written study directions

5. Must not be taking or be willing to take any supplements containing any form of niacin for seven days prior to baseline and for the duration of the study.

6. Able to maintain consistent diet and lifestyle habits throughout the study

7. Male and female subjects must be willing to agree to use effective contraceptive methods while on treatment and for 3 months after the completion of study

8. Willing to consume assigned dietary supplements for 2 months

Exclusion Criteria

1. Participants on current use of prescription or over-the-counter nicotinic acid

2. Use of statin drugs

3. Having used any tobacco product or used a recreational drug in the past 6 months

4. Having abnormal screening laboratory test values or other lab test result(s) that would preclude study participation in the judgment of the investigator

5. Documented presence of atherosclerotic disease and/or cardiopulmonary disease

6. History of drug or alcohol abuse

7. History of unstable depression or mental illness within the last 6 months for which the investigator believes could impact the participantââ?¬•s ability to comply with study requirements

8. Unwilling to discontinue use of conventional multivitamin/mineral or other supplements at least two weeks prior to the study start

9. Participating in or planning to begin a weight loss diet during the study period

10. Lifestyle or schedule incompatible with the study protocol

11. Known hypersensitivity to the drug components used during the study

12. Women with positive result for urinary beta human chorionic gonadotropin or gestation period or breastfeeding

13. Other diseases or medications, according to the investigator, that would interfere directly in the results of the study or jeopardize the health of the participant.

14. Currently, or within the past 30 days, enrolled in a different clinical investigation

15. Inability to provide a venous blood sample

16. Unable or unwilling to provide written informed consent for participation in study

Study & Design

• Study Type: Interventional
• Study Design: Not specified